Nasus Pharma Ltd. (NSRX)
NYSEAMERICAN: NSRX · Real-Time Price · USD
3.815
+0.125 (3.39%)
At close: Oct 1, 2026, 4:00 PM EDT
3.771
-0.044 (-1.16%)
After-hours: Oct 1, 2026, 5:26 PM EDT
Company Description
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions.
It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose.
Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Nasus Pharma Ltd.
| Country | Israel |
| Founded | 2019 |
| IPO Date | Aug 14, 2025 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Brendan O'Grady |
Contact Details
Address: Yigal Alon 65 Tel Aviv-Yafo, 6744317 Israel | |
| Phone | 972 3 573 6632 |
| Website | nasuspharma.com |
Stock Details
| Ticker Symbol | NSRX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 2029039 |
| ISIN Number | IL0012181553 |
| Employer ID | 51-6022712 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ehud Moshe Gilboa MBA | Co-Founder and Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 18, 2026 | 424B5 | Filing |
| Sep 18, 2026 | 6-K | Report of foreign issuer |
| Sep 14, 2026 | 6-K | Report of foreign issuer |
| Sep 11, 2026 | EFFECT | Notice of Effectiveness |
| Sep 4, 2026 | 6-K | Report of foreign issuer |
| Sep 1, 2026 | F-3 | Filing |
| Aug 20, 2026 | EFFECT | Notice of Effectiveness |
| Aug 19, 2026 | 6-K | Report of foreign issuer |
| Aug 19, 2026 | POS AM | Post-Effective amendments for registration statement |
| Aug 17, 2026 | 6-K | Report of foreign issuer |